Make an Appointment

Ask a Question
Refer a Patient

1.877.CALL NJH

Scleroderma Lung Study II (SLSII)

Trial Location:
Main Campus, Denver, CO
Principal Investigator:

Kevin K. Brown, MD
Aryeh Fischer, MD

Trial Sponsor(s):

National Heart Blood and Lung Institute(NHLBI)
National Institutes of Health 

Trial Objective:

The objective is to determine if a 2-year course of Mycophenolate (CellCept) will be safer and more effective than treatment with a 1-year course of oral Cyclophosphamide (Cytoxan) in patients suffering from active and symptomatic Scleroderma Interstitial Lung Disease.

Patient Groups:
150 patients will be enrolled from 12 sites with 1/2 of the patients receiving CellCept and the other 1/2 receiving Cytoxan.

Study Visits:
Approximately 28 visits over a 2-year period.


Not Provided

Who Can Participate:

  • Age 18-75 years old
  • The presence of either limited or diffuse scleroderma
  • Shortness of breath with exertion

Active Clinical Trials Closed to Recruitment